STRYKER (SYK) Company Report

Continued fast growth driven by prioritized M&A in high-growth areas (e.g., healthcare IT with Vocera, Care.ai and Inari) to raise the weighted average market growth rate
Decentralized operating model with specialized business units (GM-led sales, marketing, R&D) complemented by Customer Solutions for pricing, contracting and ASC programs to deliver comprehensive offerings
Financial commitment to double-digit EPS growth in 2026–2028, with ~70% of capital allocated to acquisitions, moderate dividend increases and no share buybacks planned
Emphasis on innovation across power brands—including robotics, 3D-printed implants, the virtual nurse (Care.ai) and the newly FDA-cleared MAKO RPS handheld robotic system for joint replacement’s standard-of-care segment

Nov 13, 2025, 7:30 PM

Transcript

Stryker Reports 10% Q3 Sales Growth, Raises 2025 Guidance

SYK

Earnings

Guidance Update

Product Launch

Third-quarter net sales rose 10.3% to $6.1 billion, and adjusted EPS increased 11.1% to $3.19, outperforming expectations.
Full-year outlook raised to 9.8%–10.2% organic net sales growth and $13.50–$13.60 adjusted EPS.
Operating income margin was 18.7% (adjusted 25.6%), while free cash flow margin declined to 22.3% from 23.7%, indicating some margin pressure.
Innovation pipeline advanced with the FDA-cleared Incompass total ankle system launch and a neurovascular robotics partnership with Siemens Healthineers.

Oct 31, 2025, 6:04 AM

WSJ

Stryker reports Q3 2025 results

SYK

Earnings

Guidance Update

M&A

Delivered 9.5% organic sales growth and $3.19 adjusted EPS (+11.1% y/y) in Q3 2025
Raised full-year 2025 guidance to 9.8%–10.2% organic sales growth and $13.50–$13.60 EPS
Achieved 65% adjusted gross margin (+50 bps) and 25.6% adjusted operating margin (+90 bps) despite ~$200 million tariff impact
Completed tuck-in acquisitions of Guard Medical NP Seal and Advanced Medical Balloons and advanced Inari integration with $590 million pro forma sales in 10 months

Oct 30, 2025, 8:30 PM

Transcript

Stryker reports Q3 2025 results and raises full-year outlook

SYK

Earnings

Guidance Update

M&A

Organic sales grew 9.5% year-over-year and adjusted EPS was $3.19, up 11.1%, driven by strong demand across businesses.
Adjusted gross margin reached 65% (up 50 bp) and adjusted operating margin was 25.6% (up 90 bp); year-to-date operating cash flow was $2.9 billion.
MedSurg & Neurotechnology sales rose 8.4% (U.S. +9.4%, International +5.1%) and Orthopaedics grew 11.4% (U.S. +12.9%, International +7.8%).
Completed small tuck-in acquisitions of Guard Medical’s NP Seal and Advanced Medical Balloons and emphasized continued M&A activity.
Raised full-year 2025 guidance to 9.8%–10.2% organic net sales growth and $13.50–$13.60 adjusted EPS.

Oct 30, 2025, 8:30 PM

Transcript

Stryker reports Q3 2025 results

SYK

Earnings

Guidance Update

M&A

Delivered 9.5% organic sales growth and 11.1% adjusted EPS growth to $3.19 in Q3 2025.
Raised full-year 2025 outlook to 9.8–10.2% organic net sales growth and $13.50–$13.60 adjusted EPS.
Achieved 11.4% organic growth in Orthopaedics (U.S. 12.9%, international 7.8%) and 8.4% in MedSurg & Neurotechnology (U.S. 9.4%, international 5.1%).
Expanded margins with a 65% adjusted gross margin (+50 bps) and 25.6% operating margin (+90 bps), partly offset by an estimated $200 million tariff headwind for 2025.
Completed tuck-in acquisitions of NP Seal and Advanced Medical Balloons; recorded best-ever MEKO installations; launched Lifepak 35 in Europe; Inari integration drove double-digit pro forma growth and ~$590 million in 10-month sales.

Oct 30, 2025, 8:30 PM

Transcript

Stryker reports Q3 2025 operating results

SYK

Earnings

Guidance Update

Stryker reported Q3 net sales of $6.1 billion, up 10.3% year-over-year; organic net sales grew 9.5%.
Reported operating margin was 18.7%, while adjusted operating margin rose 90 bps to 25.6%.
Reported EPS was $2.22 (+2.8%), and adjusted EPS was $3.19 (+11.1%).
Raised full-year 2025 guidance to 9.8%–10.2% organic net sales growth and $13.50–$13.60 adjusted EPS.
MedSurg & Neurotechnology sales climbed 14.4% to $3.8 billion, and Orthopaedics sales increased 3.9% to $2.3 billion.

Oct 30, 2025, 8:15 PM

8-K

Stryker reports Q3 2025 operating results

SYK

Earnings

Guidance Update

Revenue Acceleration/Inflection

Net sales rose 10.3% year-over-year to $6.1 billion, driven by 9.5% organic growth.
Adjusted operating margin expanded 90 bps to 25.6%, while reported margin was 18.7%.
Adjusted EPS increased 11.1% to $3.19; reported EPS was $2.22, up 2.8%.
Organic net sales by segment: MedSurg & Neurotech $3.8 billion (+8.4% organic), Orthopaedics $2.3 billion (+11.4% organic).
Raised full-year 2025 guidance for organic net sales growth to 9.8–10.2% and adjusted EPS to $13.50–$13.60.

Oct 30, 2025, 8:05 PM

Press Release

Stryker launches next-gen InThrill Thrombectomy System

SYK

Product Launch

M&A

Stryker’s Inari division launched the next-generation InThrill Thrombectomy System on July 29, 2025, marking the first purpose-built small vessel and arteriovenous access thrombectomy device.
The 8 French over-the-wire system features increased radial force, offset single open mouth, internal struts, and a redesigned backend to optimize clot removal and user ergonomics.
The first commercial case occurred on May 19, 2025 at UPMC, with physicians reporting more effective and consistent thrombectomies.
Stryker completed its acquisition of Inari Medical on February 19, 2025, integrating Inari’s vascular device expertise into its portfolio.

Jul 29, 2025, 1:07 PM

Press Release

Stryker gains FDA clearance for Incompass Total Ankle System

SYK

Product Launch

M&A

Stryker received FDA 510(k) clearance for its Incompass Total Ankle System, integrating Inbone and Infinity platform technologies to enhance long-term fixation and procedural efficiency.
The implant was developed using the SOMA platform and Prophecy Surgical Planning System, leveraging data from 85,000 CT scans and 100,000 clinical cases for personalized patient anatomy alignment.
In Q1 2025, Stryker delivered 10.1% organic sales growth, an adjusted operating margin of 22.9% (up 100 bps year-over-year), and a 121.01% five-year total shareholder return.
Earlier in 2025, Stryker expanded into the venous thromboembolism market by acquiring Inari Medical for nearly $4.9 billion.

Jun 25, 2025, 1:45 PM

Morningstar

Stryker Outlines Growth Initiatives and Pricing Strategy in Special Call

SYK

M&A

Revenue Acceleration/Inflection

Product Launch

Differentiated commercial model drives sustained double-digit revenue growth supported by both internal innovation and proactive M&A, including the recent divestiture of the Spine business and acquisition of Inari.
Pricing strategies have been refined to mitigate tariff impacts and improve product margin performance, contributing to more positive pricing outcomes across segments.
The company reports a robust capital order book with a strong pipeline in its Orthopaedics and MedSurg businesses, signaling a healthy outlook for future growth.

May 13, 2025, 8:41 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for STRYKER.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Kevin Lobo say about margins?What are STRYKER's strategic priorities?How is STRYKER positioned vs competitors?How did STRYKER do last quarter?

Let Fintool AI Agent track STRYKER's earnings for you

Get instant analysis when filings drop